×
Cingulate Net Current Debt 2021-2025 | CING
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Cingulate net current debt from 2021 to 2025. Net current debt can be defined as the net amount of debt repaid and issued with short-term maturities.
View More
Cingulate Net Current Debt 2021-2025 | CING
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Cingulate net current debt from 2021 to 2025. Net current debt can be defined as the net amount of debt repaid and issued with short-term maturities.
Related Stocks
Company Name
Market
Cap
AstraZeneca (AZN)
$246.7B
Amgen (AMGN)
$159.1B
Gilead Sciences (GILD)
$146.4B
Vertex Pharmaceuticals (VRTX)
$100.2B
Bristol Myers Squibb (BMY)
$98.4B
GSK (GSK)
$80.7B
CSL (CSLLY)
$70.8B
Regeneron Pharmaceuticals (REGN)
$60.6B
Alnylam Pharmaceuticals (ALNY)
$60.1B
Argenex SE (ARGX)
$40.2B
Insmed (INSM)
$26.9B
BioNTech SE (BNTX)
$26.8B
Royalty Pharma (RPRX)
$21B
Biogen (BIIB)
$20.4B
Incyte (INCY)
$16.7B
Illumina (ILMN)
$15.6B
Genmab (GNMSF)
$15.3B
Genmab (GMAB)
$15.3B
Ascendis Pharma (ASND)
$11.9B
BioMarin Pharmaceutical (BMRN)
$11B
QIAGEN (QGEN)
$10.9B
Moderna (MRNA)
$10.9B
Swedish Orphan Biovitrum (BIOVF)
$10.3B
Exelixis (EXEL)
$10.1B
Verona Pharma American Depositary Share (VRNA)
$9B
Exact Sciences (EXAS)
$8.6B
Bio-Techne Corp (TECH)
$8.6B
Blueprint Medicines (BPMC)
$8.3B
Halozyme Therapeutics (HALO)
$8.2B
Roivant Sciences (ROIV)
$8B